IL6 and obesity disorder: Adipose tissue is known to release interleukin-6,20 which indirectly induces B lymphocyte antibody production via T lymphocyte derived interleukin-21.21 Furthermore, increased BMI is associated with low-grade systemic inflammation evidenced by increased serum C reactive protein, an acute phase protein that is IL-6 dependent.22 23 Further studies exploring the relationship between obesity, adiposity, baseline IL-6 levels and the magnitude and quality of antiviral antibody responses may facilitate enhanced patient selection when considering the use of IL-6 blockade in COVID-19 infection.24